Our team is also conducting research on autologous insulin-producing cell-based agents for type 1 diabetes and autologous MSC-based agents for stroke, and investigator-initiated clinical trials of combination products of MSCs and biomaterials are underway [46,47,48,49]. This evidence concerns the gene INS and stroke disorder.